Complete Response Letters
Polarean Inc.: Xenoview
What FDA's Complete Response Letters to the company say, in the letters' own words.
Complete Response Letter, Oct 5, 2021
1. The degree of polarization of xenon-129 hyperpolarized is a critical quality attribute of the drug component in your drug-device combination product.
CRL_NDA214375_20211005:p1:s20Submit to the application the master batch record and executed batch records for production of xenon-129 hyperpolarized from hyperpolarizer © manufactured)
CRL_NDA214375_20211005:p1:s29During a recent inspection of the Polarean Inc. (FEI:3010132318) manufacturing facility or this application, our field investigator conveyed deficiencies to the representative of he facility.
CRL_NDA214375_20211005:p2:s9Satisfactory resolution of these deficiencies is required before this application may be approved.
CRL_NDA214375_20211005:p2:s10During a recent inspection of the we manufacturing facility for this application, our field investigator conveyed deficiencies to he representative of the facility.
CRL_NDA214375_20211005:p2:s11More Complete Response Letters
Updated Sep 30, 2026 · built from 283 companies in the EphemerisX knowledge graph. This page is regenerated as companies are added.